Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Market Closed - Nasdaq Other stock markets 01:30:00 12/03/2026 am IST			5-day change	1st Jan Change
129.54 ^USD	-0.25%		-2.92%	-8.67%

09/03	Neurocrine Biosciences, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 08:40 AM
04/03	Neurocrine Biosciences, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:50 AM

Transcript : Neurocrine Biosciences, Inc. Presents at TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit 2024, Sep-26-2024 11

Published on 09/26/2024 at 08:30 pm IST

S&P Capital IQ

Presenter Speech
Philip Nadeau (Analysts)

Good morning, and welcome to TD Cowen's Neuropsych Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to moderate a

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Neurocrine Biosciences, Inc.

09/03	Neurocrine Biosciences, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 08:40 AM
04/03	Neurocrine Biosciences, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:50 AM
13/02	UBS Adjusts Price Target on Neurocrine Biosciences to $161 From $178, Maintains Buy Rating	MT
12/02	Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says	MT
12/02	Wedbush Adjusts Neurocrine Biosciences Price Target to $151 From $149, Maintains Outperform Rating	MT
12/02	RBC Trims Price Target on Neurocrine Biosciences to $177 From $180, Keeps Outperform Rating	MT
12/02	Morgan Stanley Trims Price Target on Neurocrine Biosciences to $173 From $175, Keeps Equalweight Rating	MT
12/02	Neurocrine Biosciences, Inc., Q4 2025 Earnings Call, Feb 11, 2026
12/02	Neurocrine Biosciences Fiscal Q4 Adjusted Earnings, Revenue Rise; Sets INGREZZA FY Guidance	MT
12/02	Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q4 Revenue $805.5M, vs. FactSet Est of $790.5M	MT
12/02	Tranche Update on Neurocrine Biosciences, Inc.'s Equity Buyback Plan announced on February 21, 2025.	CI
12/02	Neurocrine Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
12/02	Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q4 Revenue $805.5M, vs. FactSet Est of $790.5M	MT
12/02	Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Posts Q4 Adjusted EPS $1.88 per Share, vs. FactSet Est of $1.80	MT
12/02	Neurocrine Biosciences, Inc. Provides Product Sales Guidance for the Fiscal Year 2026	CI